₹3,551.80
₹-3.10 (-0.09%)
Closed · As of 26 Aug 3:30 pm
Mkt Cap
₹44,450 Cr
P/E
39.17
ROE
23.33%
ROCE
29.09%
About Ajanta Pharma Ltd
Ajanta Pharma is primarily involved in development manufacturing and marketing of speciality pharmaceutical finished dosages.(Source : AR-PDF:202603-01 Pg No:109)
Founded
1979
CEO
Mannalal B Agrawal
Employees
13,206
HQ
Mumbai, India
About Ajanta Pharma Ltd
Ajanta Pharma is primarily involved in development manufacturing and marketing of speciality pharmaceutical finished dosages.(Source : AR-PDF:202603-01 Pg No:109)
Founded:1979
CEO:Mannalal B Agrawal
Employees:13,206
HQ:Mumbai, India
Finished Products
1Sales
₹19,445.70Cr2Other Operating Revenues
₹245.29CrRaw Materials
1Raw Material Consumed
₹3,654.39Cr2Purchase of Stock-in-Trade
₹829.38Cr3Packing Material
₹699.56CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹3,796
52W Low
₹2,330
Volume35.23K
Avg VolumeN/A
Beta0.54
Dividend Yield0.79%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
39.17x
Valuation
P/B Ratio
9.82x
Valuation
EPS
₹90.82
Valuation
Dividend Yield
0.79%
Valuation
ROE
23.33%
Profitability
ROCE
29.09%
Profitability
Revenue by Segment
Contribution & growth by business line
Pharmaceutical ProductsRevenue split N/A
Geographical Revenue Split
Domestic vs international exposure
Domestic
30.6%
International
69.4%
Emerging Market37.7%
India30.6%
USA28.8%
Africa Institution3.0%
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.06x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
9.0%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.